NEW YORK, August 20, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Covidien PLC (NYSE: COV), Mylan, Inc. (NASDAQ: MYL), Baxter International Inc. (NYSE: BAX), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Perrigo Company PLC (NYSE: PRGO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5849-100free.

-- Covidien PLC Research Reports On August 15, 2014, shares of Covidien PLC (Covidien) retreated 0.17% from its previous days close to end the trading session at $87.11. A total of 4.0 million shares were traded, lower than the 30-day average trading volume of 5.47 million shares. The stock is trading near its 52-week high of $92.68, which it achieved on June 16, 2014. Year-till-date the stock has returned 28.27%, outperforming the NYSE Composite which gained an upside of 4.23%, during the same time period. The full research reports on Covidien are available to download free of charge at:

http://www.analystsreview.com/Aug-20-2014/COV/report.pdf

-- Mylan, Inc. Research Reports On August 11, 2014, Mylan, Inc. (Mylan) announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda(R) Tablets. Mylan received the final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers. Mylan's CEO Heather Bresch said, "The approval of this product, one of a number of key approvals that had been pending with FDA, adds an important product to our broad and growing oncology franchise. We look forward to bringing a lower cost generic version of this product to patients." The full research reports on Mylan are available to download free of charge at:

http://www.analystsreview.com/Aug-20-2014/MYL/report.pdf

-- Baxter International Inc. Research Reports On August 7, 2014, Baxter International Inc. (Baxter) announced the opening of its first advanced recombinant biologic facility in Singapore, and expansion plans for a new recombinant protein processing suite. According to the Company, the current suite supports the processing of ADVATE [Antihemophilic Factor (Recombinant)]1, the market leading full-length recombinant factor VIII (rFVIII) worldwide for the treatment of patients with hemophilia A. The Company added that the second suite will initially process RIXUBIS [Coagulation Factor IX (Recombinant)]2, a recombinant factor IX (rFIX) protein for the treatment of adults with hemophilia B and, when operational, will be the primary global commercial processing facility. Ludwig Hantson, Ph.D., President of Baxter BioScience commented, "As a long-standing, established leader in the global hemophilia community, Baxter has focused efforts on improving standards of care for people with hemophilia. The opening of the Singapore facility reinforces our continued commitment to expanding access to advanced, high quality treatments for patients around the world." The full research reports on Baxter are available to download free of charge at:

http://www.analystsreview.com/Aug-20-2014/BAX/report.pdf

-- Achillion Pharmaceuticals, Inc. Research Reports On August 15, 2014, shares of Achillion Pharmaceuticals, Inc. (Achillion) gained as much as 17.78% to end the trading session at $9.25, up 9.60%. The rally in Achillion's stock followed positive data from the Company's eight-week Phase 2 Trial evaluating the combination of ACH-3102 and sofosbuvir without ribavirin for treatment of patients with genotype I chronic hepatitis C virus (HCV) infection. The Company stated that of the 12 patients treated, 100% (n=12/12) remained HCV RNA undetectable four weeks after completing therapy (SVR4). According to the Company, based upon these results, 12 additional patients will begin treatment with six weeks of once daily ACH-3102 and sofosbuvir. The full research reports on Achillion are available to download free of charge at:

http://www.analystsreview.com/Aug-20-2014/ACHN/report.pdf

-- Perrigo Company PLC Research Reports On August 13, 2014, Perrigo Company PLC announced that its Board of Directors declared a quarterly dividend of $0.105 per share, payable on September 16, 2014 to shareholders of record on August 29, 2014. The full research reports on Perrigo are available to download free of charge at:

http://www.analystsreview.com/Aug-20-2014/PRGO/report.pdf

-- About Analysts Review We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

=============== EDITOR'S NOTES: ===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Analysts Review